Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.05), $0.24 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $22.3 million versus the consensus estimate of $22.97 million.

FINANCIAL GUIDANCE

REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $327.3 million as of June 30, 2024 to fund its operations into 2026. This cash runway guidance is based on the Company\'s current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under our ABBV-RGX-314 collaboration (including a potential, one-time $200.0 million milestone for achievement of first patient dosed in the first pivotal trial for suprachoroidal delivery for treatment of DR) and the potential monetization of a priority review voucher that may be received for RGX-121.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.